Hitokol

2021: Launch of the production of a remedy for the treatment of wounds in the suburbs

On May 18, 2021, it became known about the upcoming start of production of the Hitokol agent, designed for the local treatment of infected wounds. This is the development of the Evers Group Rus group of companies, which is a resident of the Dubna SEZ near Moscow.

The manufacturer claims that Hitokol helps treat wounds of any complexity, including burns, necrotic, purulent-necrotic, trophic ulcers and sores.

According to the press service of the Ministry of Investment, Industry and Science of the Moscow Region, a means in the form of a highly porous sponge of various sizes based on biologically active chitosan is used at any stage of the wound process. It is capable of biodegradation (resorption in the wound), safe and non-toxic. Hitokol has no analogues in the Russian market, and its effectiveness is confirmed by the results of scientific research, the department added.

In the suburbs, the production of a remedy for the treatment of wounds "Hitokol" for 222 million rubles

The volume of investments in the project amounted to 222 million rubles, said Ekaterina Zinovieva, Minister of Investment, Industry and Science of the Moscow Region. According to her, about 50 jobs will be created at the enterprise in the Dubna SEZ.

It is planned to launch serial production of Hitokol in the summer of 2021. The drug will be tested in the surgical departments of medical institutions in Moscow and the Moscow region.

As of May 2021, the Evers Group Rus group of companies also produces more than 200 types of medical products, including sterile gauze bandages and napkins, patch bandages pre-treated with specialized compositions of a wipe to stop bleeding and provide emergency care for various injuries, injection wipes, fixing bandages, disposable masks, wipes for stimulating breathing^[1]

Notes